In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX), with a price target of $3. The company’s shares opened today at $1.27. McCarthy commented: “Following last month’s clearance to begin its European clinical trial of WP1220 (STAT3 inhibitor) in the topical treatment of cutaneous T-cell lymphoma […]
Historical memory and how it is understood play a major role in forming civic solidarity, creating links between generations and making citizens feel like they have a personal stake in the state affairs.
){kind=link}
The evacuation of civilians from Mariupol and Volnovakha is unlikely to begin on Saturday Humanitarian corridors from the Azov Sea port city of Mariupol and the nearby city of Volnovakha are unlikely to open on Saturday and it’s still unclear when safe-passage operations might begin, a statement from the International Committee of the Red Cross…
){kind=link}